Landry Blanc

Landry Blanc

Auto-generated profile, based on publicly available information

Landry Blanc

Univ Toulouse, CNRS, IPBS, Toulouse, France

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
GFGino B. Ferraro
Gino B. Ferraro
AAAhmed Ali
Ahmed Ali
ALAlba Luengo
Alba Luengo
DKDavid P. Kodack
David P. Kodack
ADAmy Deik
Amy Deik
MHMatthew G. Vander Heiden
Matthew G. Vander Heiden

1 February 2018 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
JSJansy P. Sarathy
Jansy P. Sarathy
LVLaura E. Via
Laura E. Via
DWDanielle Weiner
Danielle Weiner
LBLandry Blanc
Landry Blanc
HBHelena Boshoff
Helena Boshoff
VDVeronique A Dartois
Veronique A Dartois
Tuberculosis (TB) recently became the leading infectious cause of death in adults, while attempts to shorten therapy have largely failed. Dormancy, persistence, and drug tolerance are among the factors driving the long therapy duration. Assays to measure in situ drug susceptibility of Mycobacterium tuberculosis bacteria in pulmonary lesions are needed if we are to discover new fast-acting regimens and address the global TB threat. Here we take a first step toward this goal and describe an ex vivo assay developed to measure the cidal activity of anti-TB drugs against M. tuberculosis bacilli present in cavity caseum obtained from rabbits with active TB. We show that caseum M. tuberculosis bacilli are largely nonreplicating, maintain viability over the course of the assay, and exhibit extreme tolerance to many first- and second-line TB drugs. Among the drugs tested, only the rifamycins fully sterilized caseum. A similar trend of phenotypic drug resistance was observed in the hypoxia- and starvation-induced nonreplicating models, but with notable qualitative and quantitative differences: (i) caseum M. tuberculosis exhibits higher drug tolerance than nonreplicating M. tuberculosis in the Wayne and Loebel models, and (ii) pyrazinamide is cidal in caseum but has no detectable activity in these classic nonreplicating assays. Thus, ex vivo caseum constitutes a unique tool to evaluate drug potency against slowly replicating or nonreplicating bacilli in their native caseous environment. Intracaseum cidal concentrations can now be related to the concentrations achieved in the necrotic foci of granulomas and cavities to establish correlations between clinical outcome and lesion-centered pharmacokinetics-pharmacodynamics (PK-PD) parameters.

5 September 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
HSHassan Safi
Hassan Safi
PGPooja Gopal
Pooja Gopal
SLSubramanya Lingaraju
Subramanya Lingaraju
SMShuyi Ma
Shuyi Ma
CLCarly Levine
Carly Levine
DADavid Alland
David Alland
The length and complexity of tuberculosis (TB) therapy, as well as the propensity of Mycobacterium tuberculosis to develop drug resistance, are major barriers to global TB control efforts. M. tuberculosis is known to have the ability to enter into a drug-tolerant state, which may explain many of these impediments to TB treatment. We have identified a mechanism of genetically encoded but rapidly reversible drug tolerance in M. tuberculosis caused by transient frameshift mutations in a homopolymeric tract (HT) of 7 cytosines (7C) in the glpK gene. Inactivating frameshift mutations associated with the 7C HT in glpK produce small colonies that exhibit heritable multidrug increases in minimal inhibitory concentrations and decreases in drug-dependent killing; however, reversion back to a fully drug-susceptible large-colony phenotype occurs rapidly through the introduction of additional insertions or deletions in the same glpK HT region. These reversible frameshift mutations in the 7C HT of M. tuberculosis glpK occur in clinical isolates, accumulate in M. tuberculosis -infected mice with further accumulation during drug treatment, and exhibit a reversible transcriptional profile including induction of dosR and sigH and repression of kstR regulons, similar to that observed in other in vitro models of M. tuberculosis tolerance. These results suggest that GlpK phase variation may contribute to drug tolerance, treatment failure, and relapse in human TB. Drugs effective against phase-variant M. tuberculosis may hasten TB treatment and improve cure rates.

30 August 2018 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
VGValentina Guerrini
Valentina Guerrini
BPBrendan Prideaux
Brendan Prideaux
LBLandry Blanc
Landry Blanc
NBNatalie Bruiners
Natalie Bruiners
RARiccardo Arrigucci
Riccardo Arrigucci
MGMaria Laura Gennaro
Maria Laura Gennaro
Foam cells are lipid-laden macrophages that contribute to the inflammation and tissue damage associated with many chronic inflammatory disorders. Although foam cell biogenesis has been extensively studied in atherosclerosis, how these cells form during a chronic infectious disease such as tuberculosis is unknown. Here we report that, unlike the cholesterol-laden cells of atherosclerosis, foam cells in tuberculous lung lesions accumulate triglycerides. Consequently, the biogenesis of foam cells varies with the underlying disease. In vitro mechanistic studies showed that triglyceride accumulation in human macrophages infected with Mycobacterium tuberculosis is mediated by TNF receptor signaling through downstream activation of the caspase cascade and the mammalian target of rapamycin complex 1 (mTORC1). These features are distinct from the known biogenesis of atherogenic foam cells and establish a new paradigm for non-atherogenic foam cell formation. Moreover, they reveal novel targets for disease-specific pharmacological interventions against maladaptive macrophage responses. The formation of foam cells (lipid-laden macrophages) is a maladaptive host response associated with chronic inflammation. Foam cell biogenesis has been most thoroughly studied in atherosclerosis, where it is linked to disruption of cholesterol homeostasis and consequent intracellular accumulation of cholesteryl esters. In this study, we show that, during pulmonary tuberculosis, foam cells found in necrotizing granulomas (tubercles) accumulate predominantly triglycerides rather than cholesteryl esters. Triglyceride profiles are highly conserved across lung granulomas in rabbits, non-human primates, and humans. We also show that triglyceride accumulation in human primary macrophages infected with Mycobacterium tuberculosis involves TNF receptor signaling and downstream activation of mTORC1 and caspase pathways. Our finding that tuberculous foam cells differ from atherogenic foam cells with respect to storage lipid composition and lipid accumulation mechanism reveals that foam cell formation is a disease-specific process. The results of this study point to novel targets for pharmacological intervention against tuberculosis and help explain links between tuberculosis and insulin resistance.

2 October 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
LBLandry Blanc
Landry Blanc
MGMartine NICOLE Gilleron
Martine NICOLE Gilleron
JPJacques Prandi
Jacques Prandi
OSOk-Ryul Song
Ok-Ryul Song
MJMi-Seon Jang
Mi-Seon Jang
JNJérôme Nigou
Jérôme Nigou
Significance: To secure their colonization and survival, pathogens have evolved tactics to undermine host immune responses. Most particularly,Mycobacterium tuberculosisinhibits the activation of macrophages, one of whose roles is to recognize and kill invading microorganisms. Here, we used a library ofM. tuberculosismutants to infect macrophages and uncover molecular mechanisms by which the pathogen modulates the function of these immune cells. We found thatM. tuberculosisproduces cell envelope glycolipids that are antagonists of a macrophage receptor, named TLR2, which is dedicated to the recognition of pathogens, thereby preventing its efficient recognition by the immune system.

1 October 2017 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
YZYanan Zhao
Yanan Zhao
BPBrendan Prideaux
Brendan Prideaux
YNYoji Nagasaki
Yoji Nagasaki
MLMin Hee Lee
Min Hee Lee
PCPei-Yu Chen
Pei-Yu Chen
David PerlinDavid Perlin
David Perlin
Intra-abdominal candidiasis (IAC) is a prominent invasive fungal infection associated with high mortality. Prompt antifungal therapy and source control are crucial for successful treatment. Echinocandin antifungal drugs are first-line agents; however, their clinical effectiveness is highly variable, with known potential for breakthrough resistance, and little is known about drug exposure at the site of infection. Using matrix-assisted desorption ionization mass spectrometry imaging technology, we investigated the spatial and quantitative distribution in tissue lesions for two echinocandin drugs, micafungin and CD101, in a clinically relevant IAC mouse model. Drug accumulation within lesions was observed with both drugs at their humanized therapeutic doses. CD101, but not micafungin, accumulated in lesions at levels above the mutant prevention concentration of the infecting strain. These findings indicate that current echinocandin drugs are limited by penetration at the site of infection and have implications for clinical outcomes and emergence of resistance in patients with IAC.